Risk-Adjusted Analysis of Relevant Outcome Drivers for Patients after More Than Two Kidney Transplants

Table 1

The distributions of variables in the investigated cohort are shown.

Distribution of recipient variables		Mean (median)	SD	Range
Number and percentage of female patients	29 (47.5%)	n.a.	n.a.	n.a.
Blood groups
0	15 (24.6%)	n.a.	n.a.	n.a.
A	35 (57.4%)
B	2 (3.3%)
AB	9 (14.8%)
Age at last transplant in years	n.a.	39.3 (39)	10.8	20–63
Number of kidney transplants/patient	n.a.	3.3 (3)	0.5	3–5
PRA max. in %	n.a.	72.8 (81.0)	29.0	0–100
PRA max. in groups
0–30%	7 (11.5%)
>30–70%	16 (26.2%)	n.a.	n.a.	n.a.
>70%	38 (62.3%)
PRA at transplant in %	n.a.	43.7 (40)	38.4	0–100
PRA at transplant in groups
0–30%	23 (37.7%)
>30–70%	17 (27.9%)	n.a.	n.a.	n.a.
>70%	21 (34.4%)
Number of HLA-DR mismatches
0	33 (54.1%)
1	21 (34.4%)	n.a.	n.a.	n.a.
2	7 (11.5%)
Number of all HLA mismatches	n.a.	1.8 (2)	1.5	0–5
Number of all HLA mismatches in groups
0–2	39 (63.9%)	n.a.	n.a.	n.a.
3–6	22 (36.1%)
Plasmapheresis	25 (41.0%)	n.a.	n.a.	n.a.
Induction therapy	46 (75.4%)	n.a.	n.a.	n.a.
Type of induction therapy:
Basiliximab (yes/no)	15 (24.1%)	n.a.	n.a.	n.a.
Thymoglobulin (yes/no)	31 (50.8%)
Cyclosporine based protocol	44 (72.1%)	n.a.	n.a.	n.a.
Tacrolimus based protocol	17 (27.9%)	n.a.	n.a.	n.a.
Mycophenolate mofetil therapy	56 (91.8%)	n.a.	n.a.	n.a.
Azathioprine therapy	5 (8.2%)	n.a.	n.a.	n.a.
Living donation	2 (3.3%)	n.a.	n.a.	n.a.
Postmortem donation after brain death	59 (96.7%)	n.a.	n.a.	n.a.
Simultaneous nephrectomy of previous graft	14 (23.0%)	n.a.	n.a.	n.a.
Number of previous operations	n.a.	1.9 (2)	0.7	0–4
Operating time in min	n.a.	163.8 (160)	59.6	70–390
Cold ischemic time in min	n.a.	1140 (1175)	384	105–2104
Number of surgical complications	n.a.	0.6 (0)	0.8	0–3
Reoperations due to complications	13 (21.3%)	n.a.	n.a.	n.a.
Primary graft non-function	12 (19.7%)	n.a.	n.a.	n.a.
Acute graft rejection episodes	31 (50.8%)	n.a.	n.a.	n.a.
Chronic graft rejection	4 (6.6%)	n.a.	n.a.	n.a.

SD = standard deviation; n.a. = not applicable.